Targeting splicing abnormalities in cancer.

Abstract excerpt

Recently splicing has been recognized as a key pathway in cancer. Although aberrant splicing has been shown to be a consequence of mutations or the abnormal expression of splicing factors (trans-effect changes) or mutations in the splicing sequences (cis-effect mutations), the connections between aberrant splicing and cancer initiation or progression are still not well understood. Here we review the mutational...

Topics

Join the communities discussing this publication.

• Mutation
• Neoplasms
• Oligonucleotides
• RNA Splicing
• RNA Splicing Factors
• Spliceosomes